SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) ...
SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, ...
SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year ...
SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies ...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...
Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...
Hosted on MSN
Why Is Myriad Genetics (MYGN) Stock Soaring Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 36.4% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and ...
Hosted on MSN
Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus
Leffler announced, "We are raising our full year revenue range to $818 million to $828 million, largely reflecting our positive Q2 revenue performance." Gross margin guidance increased to between 69.5 ...
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Piper Sandler has upgraded Myriad Genetics (NASDAQ:MYGN), a molecular diagnostic testing and precision medicine company. Analyst David Westenberg says Myriad Genetics’ management team set an overly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results